On April 28, Mindray Medical (300760.
SZ) announced its 2020 annual report.
The report shows that in 2020, Mindray Medical’s operating income is approximately 21.
026 billion yuan, a year-on-year increase of 27%; the net profit attributable to shareholders of listed companies in 2020 is approximately 6.
658 billion yuan, a year-on-year increase of 42.
The annual R&D investment was 2.
096 billion yuan, a year-on-year increase of 27.
04%, accounting for 9.
97% of total revenue in the same period.
Previously, Mindray Medical proposed to increase the proportion of overseas business to 70%.
The latest financial report shows that Mindray Medical’s overseas business will be approximately 9.
916 billion in 2020, accounting for 47.
Compared with 43.
00% in 2018, 42.
21% in 2019 is rising steadily.
Regarding the main performance drivers in 2020, Mindray said that in 2020, with the global outbreak of the new crown epidemic, monitors, ventilators, infusion pumps, and portable color Doppler ultrasound and mobile DR for medical imaging services for life information and support services The demand for life information and support services has increased significantly, and the driving effect on life information and support services is particularly significant.
Starting from the second quarter of 2020, the company began to export COVID-19 IgG/IgM antibody detection reagents to overseas markets, which made up for part of the impact of the epidemic on the in vitro diagnostic business.
At the same time, thanks to the gradual recovery of domestic conventional reagent consumption, the in vitro diagnostic business is reporting Accelerated recovery was achieved during the period.
After the test of this round of the epidemic, the company's brand influence and recognition in the domestic and international markets have been greatly improved, and breakthroughs have been achieved in many high-end market customer groups, bringing more opportunities for the company's future growth.
At the same time, the company continued to strengthen internal management to improve operating efficiency, and was affected by the reduction in marketing and travel during the epidemic period, and its operating performance showed a healthy and good growth trend.
As of today's close, Mindray Medical has offered 456 yuan per share, with a market value of 554.
3 billion yuan.
In 2020, the market value of Mindray Medical has soared, exceeding the 500 billion mark, and it has surpassed Hengrui Pharmaceuticals this year, becoming the new "medical brother".
Today, the market value of Mindray Medical has surpassed Hengrui Pharmaceuticals by over 100 billion.
Mindray Medical was listed on the New York Stock Exchange in 2006 and returned to China from privatization in 2016, with a market value of 23 billion yuan ($3.
3 billion) at the time of delisting.
In October 2018, Mindray Medical (300760) returned to A-shares, and broke through 44% on the first day of listing, with a total market value of 85.
4 billion yuan.
In two and a half years, Mindray Medical’s stock price today is 456 yuan/share compared to the issue price of 48.
8 yuan/share, which has skyrocketed nearly 10 times.
It is worth noting that Mindray released the first quarter report of 2021 in the same period today.
The report shows that the company's operating income in the first quarter was 5.
781 billion yuan, a year-on-year increase of 21.
The net profit attributable to shareholders of listed companies was 1.
715 billion yuan, a year-on-year increase of 30.
The net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 1.
696 billion yuan, a year-on-year increase of 35.
pdf" target="_blank">Mindray Medical's 2020 Financial Report
pdf" target="_blank">Mindray Medical's 2020 Financial ReportMindray Medical's 2020 Financial ReportMindray Medical's 2020 Financial Report